Upstream Bio (NASDAQ:UPB) Upgraded by Mizuho to “Strong-Buy” Rating

Upstream Bio (NASDAQ:UPB) was upgraded by investment analysts at Mizuho to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Several other brokerages also recently issued reports on UPB. Lifesci Capital started coverage on Upstream Bio in a research report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, October 8th. Truist Financial assumed coverage on Upstream Bio in a research note on Tuesday, October 14th. They issued a “buy” rating and a $47.00 price target for the company. Finally, Evercore ISI began coverage on Upstream Bio in a report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Upstream Bio Stock Up 5.4%

UPB stock opened at $29.86 on Thursday. The stock has a market cap of $1.61 billion, a PE ratio of -15.88 and a beta of 1.83. The firm’s 50-day simple moving average is $25.14 and its 200 day simple moving average is $18.35. Upstream Bio has a fifty-two week low of $5.14 and a fifty-two week high of $33.00.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Wednesday, November 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.15. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%. The firm had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.65 million. Equities analysts forecast that Upstream Bio will post -4.3 EPS for the current fiscal year.

Institutional Trading of Upstream Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Nuveen LLC acquired a new stake in shares of Upstream Bio in the first quarter valued at $138,000. Velan Capital Investment Management LP bought a new stake in Upstream Bio in the first quarter worth about $655,000. ADAR1 Capital Management LLC acquired a new stake in Upstream Bio in the 1st quarter valued at about $92,000. AQR Capital Management LLC bought a new position in shares of Upstream Bio during the 1st quarter valued at about $115,000. Finally, Parkman Healthcare Partners LLC bought a new position in shares of Upstream Bio during the 1st quarter valued at about $1,429,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.